Advanced in Generalized Tonic-Clonic Seizure

Tetsuya Ueda

Tokyo, JP 
Advanced in Generalized Tonic-Clonic Seizure
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Tetsuya Ueda practices in Tokyo, Japan. Mr. Ueda is rated as an Advanced expert by MediFind in the treatment of Generalized Tonic-Clonic Seizure. His top areas of expertise are Sturge-Weber Syndrome, Parkes Weber Syndrome, Generalized Tonic-Clonic Seizure, and Seizures.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Generalized Tonic-Clonic Seizure.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Habikino, Japan
Kyoto, Japan
Fujioka, Japan
Osaka, Japan
Itabashi, Japan
Nerima, 1778521, Japan
Chiba, Japan
Yamanashi, Japan
Higashi-osaka, Japan
Suita, Japan
Gifu-shi, Japan
Ikoma, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3

92 Total Publications

Neurodevelopmental milestone acquisition following early hemispherotomy in Sturge-Weber syndrome.
Neurodevelopmental milestone acquisition following early hemispherotomy in Sturge-Weber syndrome.
Journal: Seizure
Published: June 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ueda's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile